These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 23178157

  • 1. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
    Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL.
    Ophthalmology; 2013 Feb; 120(2):328-33. PubMed ID: 23178157
    [Abstract] [Full Text] [Related]

  • 2. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
    Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
    [Abstract] [Full Text] [Related]

  • 3. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 4. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
    Petrarca R, Dugel PU, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Retina; 2014 May; 34(5):874-9. PubMed ID: 24169101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
    Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL, CABERNET Study Group.
    Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
    [Abstract] [Full Text] [Related]

  • 7. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
    Jackson TL, Desai R, Simpson A, Neffendorf JE, Petrarca R, Smith K, Wittes J, Lewis C, Membrey L, Haynes R, Costen M, Steel DH, Muldrew A, Chakravarthy U, Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group.
    Ophthalmology; 2016 Jun; 123(6):1287-96. PubMed ID: 27086023
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. One-year results from clinical practice of epimacular strontium-90 brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to AMD.
    Zur D, Loewenstein A, Barak A.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):338-43. PubMed ID: 25856820
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study.
    Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, Heier JS, Jefferys JL, Singerman LJ, Solomon SD.
    Ophthalmology; 2012 Apr; 119(4):771-8. PubMed ID: 22297028
    [Abstract] [Full Text] [Related]

  • 18. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
    Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, Zavala-Ayala A, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.
    Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.